finanzen.net

Johnson Johnson Aktie WKN: 853260 / ISIN: US4781601046
Symbol: JNJ

124,14EUR
+0,06EUR
+0,05%
24.05.2019
138,85USD
-0,94USD
-0,67%
24.05.2019
KAUFEN
VERKAUFEN
mehr Daten anzeigen

Johnson Johnson News

26.04.19
Johnson & Johnson erhöht die Dividende das 57. Jahr in Folge (MyDividends)
02.01.19
Johnson & Johnson gibt Dividende für das erste Quartal bekannt (MyDividends)
18.12.18
Johnson & Johnson bestätigt Prognose und kauft eigene Aktien zurück (MyDividends)
11.12.18
Johnson & Johnson schüttet Dividende für das vierte Quartal aus (MyDividends)
08.11.18
Johnson & Johnson startet die Africa Innovation Challenge 2.0. (Newsaktuell)
19.10.18
Johnson & Johnson gibt Dividende für das vierte Quartal bekannt (MyDividends)
11.09.18
Johnson & Johnson zahlt Dividende aus (MyDividends)
17.07.18
Johnson & Johnson schüttet Dividende aus (MyDividends)
12.06.18
Johnson & Johnson schüttet Dividende aus (MyDividends)
05.06.18
Johnson & Johnson Announces Progress Toward Health for Humanity Goals (EN, Johnson & Johnson)
27.04.18
Johnson & Johnson erhöht die Dividende das 56. Jahr in Folge (MyDividends)
06.04.18
Johnson & Johnson Institute Adds Innovative Analytics-Based Learning Platform to Help Surgeons Improve Technical Skills and Clinical Outcomes Across a Range of Specialties (EN, Johnson & Johnson)
23.03.18
Janssen Announces Positive CHMP Opinion for JULUCATM? (dolutegravir/rilpivirine) (EN, Johnson & Johnson)
20.03.18
Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson (EN, Johnson & Johnson)
15.03.18
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer (EN, Johnson & Johnson)
02.01.18
Aktionäre von Johnson & Johnson erhalten seit 1944 eine Dividende (MyDividends)
22.11.17
Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection (EN, Johnson & Johnson)
07.11.17
NEW PHASE 2 DATA SHOW TREATMENT WITH TREMFYA® (GUSELKUMAB) IMPROVED PSORIATIC ARTHRITIS SYMPTOMS THROUGH ONE YEAR (EN, Johnson & Johnson)
03.11.17
INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease (EN, Johnson & Johnson)
02.11.17
Newly Created Johnson & Johnson Institute Will Address Global Needs in Healthcare Professional Education (EN, Johnson & Johnson)
01.11.17
Johnson & Johnson Health Partner Leverages the Science of Behavior Change with Technology to Help Patients Better Prepare for Surgery and Recovery (EN, Johnson & Johnson)
30.10.17
New VA and Johnson & Johnson Campaign Encourages Public to Take Note of Veterans at Risk for Suicide (EN, Johnson & Johnson)
27.10.17
DEPUY SYNTHES LAUNCHES THE FIRST 3D SIMULATION ASSISTED ORTHOPAEDIC EXTERNAL CIRCULAR FIXATION DEVICE FOR PATIENTS WITH LIMB DEFORMITY (EN, Johnson & Johnson)
27.10.17
New DePuy Synthes Spine Technologies Help Simplify Minimally Invasive Surgery by Enhancing Efficiency and Reducing Steps (EN, Johnson & Johnson)
25.10.17
Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial (EN, Johnson & Johnson)
24.10.17
OneTouch® Blood Sugar Monitoring System Shown to Exceed Accuracy Standard and Improve Glycemic Control in Two New Studies (EN, Johnson & Johnson)
21.10.17
JANSSEN RECEIVES TWO U.S. FDA APPROVALS FOR SIMPONI ARIA® (GOLIMUMAB) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS OR ACTIVE ANKYLOSING SPONDYLITIS (EN, Johnson & Johnson)
20.10.17
Johnson & Johnson schüttet seit 1944 eine Dividende aus (MyDividends)
19.10.17
Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1 (EN, Johnson & Johnson)
19.10.17
Johnson & Johnson Medical GmbH to Acquire Surgical Process Institute (EN, Johnson & Johnson)
12.10.17
New System Designed to Enhance Implant Fixation for Hip Fracture Patients with Poor Bone Quality Launches in the U.S. (EN, Johnson & Johnson)
11.10.17
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer (EN, Johnson & Johnson)
27.09.17
Health Systems Can Lower Operational Costs and Reduce Environmental Impact with CareAdvantage from the Johnson & Johnson Medical Devices Companies (EN, Johnson & Johnson)
21.09.17
Research Shows That Canadian Military Servicemembers and First Responders Struggle to Get Support for Their Own Health Needs (EN, Johnson & Johnson)
18.09.17
NEW TWO-YEAR TREMFYA™ (GUSELKUMAB) DATA SHOW PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS ACHIEVED CONSISTENT RATES OF SKIN CLEARANCE (EN, Johnson & Johnson)
15.09.17
JANSSEN RECEIVES CHMP POSITIVE OPINION FOR GUSELKUMAB RECOMMENDING APPROVAL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE EUROPEAN UNION (EN, Johnson & Johnson)
15.09.17
Johnson & Johnson Announces Collaboration with U.S. Department of Health and Human Services to Fight Influenza (EN, Johnson & Johnson)
14.09.17
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results (EN, Johnson & Johnson)
14.09.17
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer (EN, Johnson & Johnson)
13.09.17
Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies (EN, Johnson & Johnson)
Seite: 12

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
TeslaA1CX3T
CommerzbankCBK100
NEL ASAA0B733
Amazon906866
BayerBAY001
Apple Inc.865985
BASFBASF11
Infineon AG623100
Ballard Power Inc.A0RENB
SteinhoffA14XB9
Deutsche Telekom AG555750
Volkswagen (VW) AG Vz.766403